Literature DB >> 17154650

Biomarkers for the development of cancer vaccines: current status.

John Copier1, Mike Whelan, Angus Dalgleish.   

Abstract

Significant improvements in our knowledge of tumor immunology have resulted in more sophisticated vaccine approaches for the treatment of cancer. However, research into biomarkers that correlate with the clinical outcome of immunotherapy has lagged behind vaccine development. To this extent, very few immunological or other markers exist that can be used in clinical trials for immunotherapy. In this review, we discuss the current status of biomarker development specifically for the monitoring and development of cancer vaccines. This includes immunological biomarkers (measurement of T-cell and cytokine responses), autoimmunity as a correlate for treatment outcome, and the possible development of multiple biomarkers using high-throughput proteomics technologies. The generation of such biomarkers will allow us to make clinical decisions about patient treatment at an earlier stage and should aid in shortening the development time for vaccines.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17154650     DOI： 10.1007/BF03256210

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


  55 in total

Review 1.  Advancing cancer biotherapy with proteomics.

Authors:  David F Stroncek; Christine Burns; Brian M Martin; Leonardo Rossi; Francesco M Marincola; Monica C Panelli
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

2.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

Authors:  Gennadi V Glinsky; Olga Berezovska; Anna B Glinskii
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 3.  Surveillance programs for early stage non-seminomatous testicular cancer: a practice guideline.

Authors:  R Segal; H Lukka; L H Klotz; A Eady; N Bestic; M Johnston
Journal:  Can J Urol       Date:  2001-02       Impact factor: 1.344

4.  Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.

Authors:  F Fallarino; U Grohmann; R Bianchi; Carmine Vacca; M C Fioretti; P Puccetti
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

5.  Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.

Authors:  Hiroya Takeuchi; Donald L Morton; David Elashoff; Dave S B Hoon
Journal:  Int J Cancer       Date:  2005-12-20       Impact factor: 7.396

6.  Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.

Authors:  Claude Soubrane; Olivier Rixe; Jean-Baptiste Meric; David Khayat; Roger Mouawad
Journal:  Melanoma Res       Date:  2005-06       Impact factor: 3.599

7.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

8.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othonas Papadopoulos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 10.  Cytometric bead array: a multiplexed assay platform with applications in various areas of biology.

Authors:  Edward Morgan; Rudi Varro; Homero Sepulveda; Julia A Ember; John Apgar; Jerry Wilson; Larry Lowe; Roy Chen; Lalita Shivraj; Anissa Agadir; Roberto Campos; David Ernst; Amitabh Gaur
Journal:  Clin Immunol       Date:  2004-03       Impact factor: 3.969
View more
  4 in total

1.  Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.

Authors:  S Karakhanova; E Ryschich; B Mosl; S Harig; D Jäger; J Schmidt; W Hartwig; J Werner; A V Bazhin
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

2.  miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer.

Authors:  Yoshitaro Shindo; Shoichi Hazama; Yusuke Nakamura; Yuka Inoue; Shinsuke Kanekiyo; Nobuaki Suzuki; Hiroko Takenouchi; Ryouichi Tsunedomi; Masao Nakajima; Tomio Ueno; Shigeru Takeda; Shigefumi Yoshino; Kiyotaka Okuno; Yusuke Fujita; Yoshihiko Hamamoto; Yutaka Kawakami; Masaaki Oka; Hiroaki Nagano
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

3.  MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.

Authors:  Taiki Kijima; Shoichi Hazama; Ryouichi Tsunedomi; Hironori Tanaka; Hiroko Takenouchi; Shinsuke Kanekiyo; Yuka Inoue; Masao Nakashima; Michihisa Iida; Kazuhiko Sakamoto; Nobuaki Suzuki; Shigeru Takeda; Tomio Ueno; Shigeru Yamamoto; Shigefumi Yoshino; Kiyotaka Okuno; Hiroaki Nagano
Journal:  Oncol Rep       Date:  2016-11-22       Impact factor: 3.906

4.  Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.

Authors:  Yoshitaro Shindo; Shoichi Hazama; Nobuaki Suzuki; Haruo Iguchi; Kazuhiro Uesugi; Hiroaki Tanaka; Atsushi Aruga; Takashi Hatori; Hidenobu Ishizaki; Yuzo Umeda; Toshiyoshi Fujiwara; Tetsuya Ikemoto; Mitsuo Shimada; Kazuhiko Yoshimatsu; Hiroko Takenouchi; Hiroto Matsui; Shinsuke Kanekiyo; Michihisa Iida; Yasunobu Koki; Hideki Arima; Hiroyuki Furukawa; Tomio Ueno; Shigefumi Yoshino; Tomonobu Fujita; Yutaka Kawakami; Yusuke Nakamura; Masaaki Oka; Hiroaki Nagano
Journal:  J Exp Clin Cancer Res       Date:  2017-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.